Mitotane in Canine Adrenal Disease and Adrenocortical Tumours

mitotane (o,p′-DDD) is covered as adrenocorticolytic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Adrenocorticolytic agents; hazardous antineoplastic medicine. Mitotane.

Mitotane.

Mitotane is a DDT derivative with selective cytotoxic effects on adrenal cortical cells and inhibition of steroid production.

Its core veterinary role is adrenal cortical suppression in hyperadrenocorticism and selected adrenocortical tumours. It is not general chemotherapy for unrelated masses and should be linked to endocrine diagnosis and hormone assessment.

Its core veterinary role is adrenal cortical suppression in hyperadrenocorticism and selected adrenocortical tumours. It is not general chemotherapy for unrelated masses and should be linked to endocrine diagnosis and hormone assessment.

Oral hazardous medicine under close veterinary endocrine or oncology supervision

Use is established in canine endocrine practice, while evidence for tumour control depends on resectability, functional status and disease extent. Hormone normalisation is not identical to eradication of an adrenal tumour.

Gastrointestinal signs, weakness, central nervous system depression, dermatitis and potentially dangerous adrenal insufficiency are recognised. Over-suppression can become an emergency.

Other glucocorticoid-modifying medicines, surgery, stress, electrolyte disorders and concurrent chemotherapy require coordinated planning. Caregivers need a clinic-issued emergency plan, not a website taper or dose.

No FDA-approved canine or feline oncology indication was established for this medicine in this audit. In the United States, veterinary oncology use of an approved human or animal formulation is extra-label and must occur under a veterinarian within AMDUCA conditions and a valid VCPR.

Multi-region specialist use; product availability, extra-label prescribing law and pharmacy handling vary by jurisdiction.

The veterinarian confirms adrenal diagnosis and functional status, reviews electrolytes and organ function and uses hormone testing and clinical signs to guide treatment. Weakness, collapse, vomiting, diarrhoea or loss of appetite can indicate urgent adrenal or drug toxicity.